
Avalon AI: Leveraging deep learning for early detection of brain diseases and improved clinical trials.
Avalon AI, founded with the mission to revolutionize medical diagnostics, focuses on leveraging deep learning technology to develop Computer Aided Diagnosis (CAD) tools. Their core vision is to facilitate early detection of brain degenerative diseases, such as Alzheimer's, and enhance patient stratification in clinical trials. Avalon AI's innovative products aim to improve diagnostic accuracy and patient outcomes, targeting healthcare providers and research institutions in the medical technology market.
Notable figures associated with Avalon AI include leading experts in artificial intelligence and neurology, though specific names are not provided. The company has secured investments from prominent venture capital firms specializing in health tech innovation. Key achievements include the successful deployment of their CAD tools in clinical settings and partnerships with major research hospitals. Avalon AI's impact lies in its potential to transform early disease detection and streamline clinical trials, ultimately contributing to better healthcare outcomes.

Avalon.Ai
avalonai.co

Altris.AI
altris.ai

Ainnova Tech
ainnovatech.com

Retina-Ai Health

Arctic Fox AI
afxmedical.com

RAD AI
radai.com

Enlitic
enlitic.com

Deep 6 AI
deep6.ai

Vytal
vytal.ai

BioticsAI
biotics.ai

Vitazi.ai
vitazi.ai

Cogniant.co
cogniant.co

AivoCode
aivocode.com

Unlearn.AI
unlearn.ai

NeuroVision Imaging
neurovision.com
Companies similar to Avalon AI include Avalon.Ai, Altris.AI, Ainnova Tech and Retina-Ai Health.
Avalon AI was founded in 2015.
Avalon AI's headquarters is located in London, Greater London, GB.
Avalon AI's most recent funding round was for $120k (USD) in June 2016.
As of Jun 20, 2016, Avalon AI has raised a total of $120k (USD).
Avalon AI has 75 employees as of Feb 4, 2024.